1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE manufacturers
- CFM-2
-
-
2026-06-02
- CAS:178616-26-7
- Purity: 99.84%
- Supply Ability: 10g
- CFM-2
-
-
2026-06-02
- CAS:178616-26-7
- Purity: 99.84%
- Supply Ability: 10g
|
| | 1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE Basic information |
| Product Name: | 1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE | | Synonyms: | CFM-2;4H-2,3-Benzodiazepin-4-one,1-(4-aminophenyl)-3,5-dihydro-7,8-dimethoxy-;1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE;CFM2,CFM 2;CFM 2, AMPA receptor antagonist;CFM-2, 10 mM in DMSO | | CAS: | 178616-26-7 | | MF: | C17H17N3O3 | | MW: | 311.34 | | EINECS: | | | Product Categories: | Glutamate receptor | | Mol File: | 178616-26-7.mol |  |
| | 1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE Chemical Properties |
| density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at RT | | solubility | Soluble in DMSO | | pka | 12.53±0.40(Predicted) | | form | Off-white solid. | | color | Light yellow to khaki |
| | 1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE Usage And Synthesis |
| Uses | CFM-2 is a non-competitive antagonist of the AMPA receptors. | | Definition | ChEBI: 1-(4-aminophenyl)-7,8-dimethoxy-3,5-dihydro-2,3-benzodiazepin-4-one is a benzodiazepine. | | Biological Activity | Novel, selective non-competitive AMPA antagonist. Highly potent, long-acting anticonvulsant. | | in vivo | Pretreatment with CFM-2 delays the progression of seizure rank during repeated administration of pentylentetrazole. At the end of the period of repeated pentylentetrazole treatment (6 weeks) the mean seizure score was 0 in vehicle treated controls, 4.3 in animals treated with vehicle + pentylentetrazole, 2.2 in rats treated chronically with CFM-2 (20 μmol/kg; i.p.) + pentylentetrazole and 1.0 in rats treated repeatedly with CFM-2 (50 μmol/kg; i.p.) + pentylenetetrazole. CFM-2 is also able to antagonize the long-term increase in sensitivity of the convulsant effects of GABA function inhibitors in pentylentetrazole-kindled animals[1].Intrathecal application of two selective non-competitive AMPAR antagonists, CFM-2 (25 and 50 μg) and GYKI 52466 (50μg), significantly attenuated mechanical and thermal hypersensitivities on the ipsilateral hind paw at 2 and 24 h post-CFA injection. Neither CFM-2 nor GYKI 52466 affects the contralateral basal responses to thermal and mechanical stimuli[4]. | | storage | Room temperature |
| | 1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE Preparation Products And Raw materials |
|